WO1993018137A1 - Culture de cellules souches hematopoietiques et leur preparation par genie genetique - Google Patents

Culture de cellules souches hematopoietiques et leur preparation par genie genetique Download PDF

Info

Publication number
WO1993018137A1
WO1993018137A1 PCT/US1993/001852 US9301852W WO9318137A1 WO 1993018137 A1 WO1993018137 A1 WO 1993018137A1 US 9301852 W US9301852 W US 9301852W WO 9318137 A1 WO9318137 A1 WO 9318137A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
medium
stem cells
cell
human hematopoietic
Prior art date
Application number
PCT/US1993/001852
Other languages
English (en)
Inventor
Chu-Chih Shih
Original Assignee
Systemix, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systemix, Inc. filed Critical Systemix, Inc.
Priority to JP5515827A priority Critical patent/JPH07504331A/ja
Priority to AU37839/93A priority patent/AU680406B2/en
Priority to KR1019940703107A priority patent/KR950700403A/ko
Priority to EP93907130A priority patent/EP0631618A4/fr
Publication of WO1993018137A1 publication Critical patent/WO1993018137A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Definitions

  • the field of this invention is expansion of human hematopoietic stem cells and their genetic modification.
  • the availability of human hematopoietic stem cell compositions offers a plethora of opportunities for medicine.
  • the hematopoietic stem cell is the progenitor for all of the blood cells, including leukocytes, including lymphocytic and myelomonocytic lineages, and erythrocytes, as well as other types of cells, such as osteoclasts.
  • leukocytes including lymphocytic and myelomonocytic lineages, and erythrocytes, as well as other types of cells, such as osteoclasts.
  • the stem cell may also lead to stromal cells. These cells provide an enormous range of functions. None of these cells is believed to be capable of self-regeneration, so as to survive during the lifetime of the host.
  • the stem cell is believed to be the only cell that is self- regenerating and maintains its pluripotent potential during the life of the host.
  • stem cell The ability to obtain substantially homogeneous human stem cell compositions offers new approaches to bone marrow transplantation. Since there is evidence to suggest that the stem cell will not be malignant, by isolating human hematopoietic stem cells, one may avoid restoring malignant cells to a host after radiation or chemotherapeutic treatment of cancer or other malignancy.
  • the stem cells offer an entree to gene therapy, where the modification will survive the life of the host.
  • inducible promoters by appropriate use of inducible promoters, one can provide that expression of various protein products may be achieved at selected levels of differentiation or in selected lineages, or even in response to particular chemical clues, such as chemoattractants, particular ligands, and the like. Also, as there is better understanding of the manner in which stem cells are directed to specific lineages, there will be the opportunity to produce in culture populations of particular lineages, such as megakaryocytes, subsets of T cells, monocytes, and the like.
  • stem cells An important aspect of this invention in the use of stem cells will be the ability to expand the stem cells in culture.
  • Growing stem cells is different from growing other cells, since in order to expand stem cells, one must not only provide for regeneration, but inhibit the loss of stem cells by differentiation. The manner in which regeneration as against differentiation is regulated in bone marrow is not understood. Methods are therefore necessary which allow for long-term retention and expansion of stem cell cultures.
  • the unique characteristics of the stem cell distinguish the stem cell from other cells which have been successfully genetically engineered.
  • efforts to genetically engineer progeny cells frequently encounter lack of transmission of functional expression of the introduced construct in progeny cells, intermittent expression, and the like. Therefore, even where one has demonstrated the successful integration of the construct, there are instances encountered where subsequent growth of the progeny cells and their differentiation result in the failure of the construct to function.
  • U.S. Patent No. 5,061,620 describes a substantially homogeneous human hematopoietic stem cell composition and the manner of obtaining such composition. See also references cited therein.
  • Stromal cell-associated hematopoiesis is described by Paul et al . , Blood (1991), 77, 1723-1733.
  • Murine leukemia inhibitory factor is taught to enhance retroviral-vector infection efficiency of hematopoietic progenitors by Fletcher et al ., Blood (1990), 76, 1098-1103.
  • Metcalf et al . , Blood. (1990), 76, 50-56 describes the effect of injected leukemia inhibitory factor on hematopoietic and other tissues in mice.
  • LIF leukemia inhibitory factor
  • LIF leukemia inhibitory factor
  • a substantially homogeneous human hematopoietic stem cell composition is genetically modified using appropriate DNA constructs for introduction into the stem cells and integration. The genetic modification of the stem cells is demonstrated by assays where long-term maintenance of expression of the integrated gene is shown in a plurality of hematopoietic lineages, both lymphocytic and myelomonocytic.
  • hHSC human hematopoietic stem cells
  • LIF leukemia inhibitory factor
  • the hHSC may be genetically modified by employing a substantially homogeneous stem cell composition with a DNA construct providing a DNA sequence of interest.
  • a retroviral vector is employed for the introduction of the DNA construct into the hHSC host.
  • the resulting cells may then be grown under conditions as described for unmodified hHSC, whereby the modified hHSC may be expanded and used for a variety of purposes.
  • the hHSC which are employed may be fresh, frozen, or have been subject to prior culture. They may be fetal, neonate, adult, obtained from fetal liver, bone marrow, blood or any other conventional source.
  • the manner in which the stem cells are separated from other cells, whether of the hematopoietic or of other lineage is not critical to this invention. Conveniently, the cells may be separated as described in U.S. Patent No. 5,061,620.
  • the substantially homogeneous composition of hHSC may be obtained by selective isolation of cells free of markers associated with differentiated cells, while displaying epitopic characteristics associated with the stem cells.
  • the stem cells are characterized by both the presence of markers associated with specific epitopic sites identified by antibodies and the absence of certain markers as identified by the lack of binding of certain antibodies. At such time as a specific marker is identified for hHSC, binding of an antibody to such marker may provide the desired composition.
  • a large proportion of the differentiated cells may be removed by initially using a relatively crude separation, where major cell population lineages of the hematopoietic system, such as lymphocytic and myelomonocytic, are removed, as well as minor populations, such as megakaryocytic, mast cells, eosinophils and basophils. Usually, at least about 70 to 90 percent of the hematopoietic cells will be removed. If desired, a prior separation may be employed to remove erythrocytes, by employing ficoll-hypaque separation.
  • the gross separation may be achieved using magnetic beads, cytotoxic agents, affinity chromatography, panning, or the like.
  • Antibodies which find use include antibodies of CD34, Class II HLA or other marker which allows for removal of most, if not all, mature cells, while being absent on hHSC. Concomitantly or subsequent to the gross separation, which provides for positive selection, a negative selection may be carried out, where antibodies to specific markers present on dedicated cells are employed.
  • these markers will include CD3 " , CD7 “ , CDS ' , CD10-, CD14", CD15-, CD19", CD20", CD33', preferably including at least CD3 ⁇ CD8-, CD10-, CD19", CD20 " , CD33 " , normally including at least CD10', CD19", CD33 ' .
  • the hematopoietic cell composition substantially depleted of dedicated cells may then be further separated using a marker for Thy-1, whereby a substantially homogeneous stem cell population is achieved.
  • exemplary of this stem cell population is a population which is CD34 + Thy-»1 + , which approximates the substantially homogeneous stem cell composition.
  • the hHSC composition is characterized by being able to be maintained in culture for extended periods of time, being capable of selection and transfer to secondary and higher order cultures, and being capable of differentiating into the various lymphocytic and myelomonocytic lineages, particularly B- and T-lymphocytes, monocytes, acrophages, neutrophils, erythrocytes, and the like.
  • a pluripotent human stem cells may be defined as follows: (1) gives rise to progeny all defined hemato- ly phoid lineages; and (2) limiting numbers of cells are capable of fully reconstituting an seriously immunocompromised human host in all blood cell types and their progenitors, including the pluripotent hematopoietic stem cell by cell renewal.
  • the hHSC are then grown in culture in an appropriate nutrient medium, which medium may be a conditioned medium, a co-culture with an appropriate stromal cell line, or a medium comprising a synthetic combination of growth factors which are sufficient to maintain the growth of hematopoietic cells.
  • an appropriate nutrient medium which medium may be a conditioned medium, a co-culture with an appropriate stromal cell line, or a medium comprising a synthetic combination of growth factors which are sufficient to maintain the growth of hematopoietic cells.
  • stromal cell lines For conditioned media or co-cultures, various stromal cell lines may be used, since it is found that human stromal cell lines are not required. Thus, other stromal cell lines may be employed, such as rodentiae, particularly urine. A number of murine stromal cell lines are described in Whitlock et al., Cell (1987), 48, 1009-1021, AC6.21 being deposited at the ATCC as . Other stromal cell lines may be developed, if desired.
  • tissue culture plates or flasks may be employed where confluent stromal cell layers may be maintained for extended periods of time without passage, but with changing of the tissue culture medium about every five to seven days.
  • the hHSC may be grown in co-culture by placing the hHSC onto the stromal cell lines, either directly or separated by a porous membrane. For example, for about 3xl0 4 to 3xl0 5 cells/ml are placed on a confluent stromal cell layer.
  • the media employed in the co-culture may be any convenient growth medium, such as RPMI-1640, IMDM, etc.
  • antibiotics to prevent bacterial growth and other additives such as pyruvate (0.1-5 mM) , glutamine (0.5-5 mM) , 2-mercaptoethanol (1-lOxlO' 5 M) and from about 5-15%, preferably about 10% of serum, e .g. fetal calf serum.
  • LIF is added in from about l ng/ml to 100 ng/ml, more usually 5 ng/ml to 30 ng/ml.
  • Other factors may also be included, such as interleukins, colony stimulating factors, steel factor, or the like.
  • LIF is IL-3, IL-6, and GM-CSF.
  • the factors which are employed may be naturally occurring or synthetic e .g. prepared recombinantly, and may be human or of other species, e.g. murine, preferably human.
  • the amount of the other factors will generally be in the range of about 1 ng/ml to 100 ng/ml.
  • the concentration will be in the range of about 5 ng/ml to 50 ng/ml, more usually 5 ng/ml to 100 ng/ml;
  • the concentration will be in the range of about 5 ng/ml to 50 ng/ml, more usually 5 ng/ml to 20 ⁇ g/ml, and for GM-CSF, the concentration will generally be 5 ng/ml to 50 ng/ml, more usually 5 ng/ml to 20 ng/ml.
  • the LIF and other factors may be present only during the initial course of the stem cell growth and expansion, usually at least 24 hours, more usually at least about 48 hours or may be maintained during the course of the expansion. Thus, it is found that significant effect can be achieved by exposure of the hHSC initially in the growth medium, without maintaining the concentration during the entire course of the expansion.
  • the cells may be grown for sufficient time to reach the desired population level.
  • at least 1X10 4 hHSC cells will be present, preferably lxlO 5 cells.
  • LIF will be present at least initially in the culture medium, usually for at least 12, more usually at least 24 h, where exposure to LIF and other growth factors may be substantially terminated. LIF and optionally the other growth factors may be maintained during the course of the growth of the cells.
  • the cells will have been grown for at least 12, usually 24 hours, in the medium with the factors, before contact with the DNA construct.
  • a retroviral vector will be employed for genetic modification of the hHSC.
  • retroviral vectors may be employed for genetic modification.
  • One will normally use combinations of retroviruses and an appropriate packaging line, where the capsid proteins will be functional for infecting human cells.
  • Various amphotropic virus-producing cell lines are known, such as PA12 (Miller et al . , Mol. Cell. Biol. 5 (1985), 431-437), PA317 (Miller et al . , Mol. Cell. Biol. 6 (1986), 2895-2902) GRIP (Danos et al . , PNAS 85 (1988), 6460-6464).
  • the cells and virus will be incubated for at least about 24 hours in the culture medium. The cells are then allowed to grow in the culture medium for at least two weeks, and may be allowed to grow for five weeks or more, before analysis.
  • the constructs which will be employed will normally include a marker, which allows for selection of cells into which the DNA has been integrated, as against cells which have not integrated the DNA construct.
  • a marker which allows for selection of cells into which the DNA has been integrated, as against cells which have not integrated the DNA construct.
  • markers exist, particularly antibiotic resistance markers, such as resistance to G418, hygromycin, and the like. Less conveniently, negative selection may be used, where the marker is the HSV-tk gene, which will make the cells sensitive to agents, such as acyclovir and gancyclovir.
  • the constructs can be prepared in a variety of conventional ways. Numerous vectors are now available which provide for the desired features, such as long terminal repeats, marker genes, and restriction sites. Thus, one may introduce the vector in an appropriate plasmid and manipulate the vector by restriction, insertion of the desired gene, with appropriate transcriptional and translational initiation and termination regions, and then introduce the plasmid into an appropriate packaging host. Thus, at each of the manipulations, one may grow the plasmid in an appropriate prokaryotic host, analyze the construct to ensure that the desired construct has been obtained, and then subject the construct to further manipulation. When completed, the plasmid or excised virus may then be introduced into the packaging host for packaging and isolation of virus particles for use in the genetic modification.
  • the introduction of DNA can be used for a wide variety of purposes, such as gene therapy, introduction of novel capabilities into the hHSC, direct dedication to a particular lineage or subset of such lineage, enhancement of maturation to a particular lineage or subset, or the like.
  • introduction of novel capabilities into the hHSC direct dedication to a particular lineage or subset of such lineage, enhancement of maturation to a particular lineage or subset, or the like.
  • the hHSC have great therapeutic potential.
  • hHSC and their progeny as carriers for the production of a wide variety of products, where the host is genetically deficient or as a result of a subsequent disease has become genetically deficient.
  • Genetic diseases involving lack of a particular natural product include muscular dystrophy, where there is a lack of dystrophin, cystic fibrosis, Alzheimer's disease, Gaucher disease, etc.
  • a particular polymorphic region of a polymorphic protein such as a T-cell receptor, major histocompatibility complex antigen, or immunoglobulin subunit
  • the particular exon may be "knocked out" by homologous recombination, so as to provide hematopoietic cells which will not be responsive to the disease.
  • the hHSC may be modified to provide for cells which will respond to the need for secretion of insulin, where appropriate enhancers and promoters may be employed, so as to have the insulin production regulated in analogous manner to the regulation in the islets of Langerhans. This may involve the expression of the insulin receptor in an appropriate hematopoietic lineage.
  • multiple drug resistance gene(s) e . g. pqp-1. may be introduced to protect the cells against cytotoxic drugs, transcription of ribozymes to protect against viral infection, or expression of various protein products to inhibit viral replication intracellularly, e .g. the tat gene with HIV.
  • Modified stem cells may also be found for use in the treatment of aging, autoimmune diseases, hematopoietic disorders, and viral infections.
  • the therapy involves removal of bone marrow or other source of stem cells from a human host, isolating the stem cells from the source and expanding the stem cells. Meanwhile, the host may be treated to substantially or complete ablate native hematopoietic capability.
  • the stem cells may be modified during this period of time, so as to provide for stem cells having the desired genetic modification. After completion of the treatment of the host, the modified stem cells may then be restored to the host to provide for the new capability. If necessary, the process may be repeated to ensure the substantial absence of the original stem cells and the substantial population of the modified stem cells.
  • the genome of the cells may be restricted and used with or without amplification.
  • the polymerase chain reaction, gel electrophoresis, restriction analysis, Southern, Northern, and Western blots may be employed, sequencing, or the like, may all be employed with advantage.
  • the cells may be grown under various conditions to ensure that the cells are capable of maturation to all of the hematopoietic lineages while maintaining the capability, as appropriate, of the introduced DNA.
  • Various tests in vitro and in vivo may be employed to ensure that the pluripotent capability of the stem cells has been maintained.
  • fetal thymus To demonstrate differentiation to T cells, one may isolate fetal thymus and culture the thymus for from 4-7 days at about 25°C, so as to substantially deplete the lymphoid population of the fetal thymus.
  • the cells to be tested are then microinjected into the thymus tissue, where the HLA of the population which is injected is mismatched with the HLA of the thymus cells.
  • the thymus tissue may then be transplanted into a scid/scid mouse as described in EPA 0 322 240, where the thymus is conveniently transplanted into the kidney capsule.
  • BFU-E units For erythrocytes, one may use conventional techniques to identify BFU-E units for example methylcellulose culture (Metcalf, In: Recent Results in Cancer Res. (1977), 61. Spinger-Verlag, Berlin, pp. 1-227) demonstrating that the cells are capable of developing the erythroid lineage.
  • the population to be tested is introduced first into a hydrocortisone containing culture and allowed to grow for six weeks in such culture.
  • the medium employed will comprise a 50:50 mixture of RPMI1640 and IMDM containing 10% FCS, 10% horse serum, 50 ⁇ g/ml streptomycin/penicillin, gluta ine and 5xl ⁇ *7 M hydrocortisone.
  • FCS 10% FCS
  • horse serum 50 ⁇ g/ml streptomycin/penicillin
  • gluta ine and 5xl ⁇ *7 M hydrocortisone it will be anticipated that in the absence of progenitor cells, all of the mature cells would die. If at the end of six weeks, myeloid cells are still observed, one may conclude that there is a progenitor cell which is providing for the continuous differentiation to myeloid cells.
  • Human hematopoietic cells grown in the presence of hydrocortisone can be maintained for at least four months.
  • human hematopoietic cell cultures can be grown in the absence of hydrocortisone for at least four months, which cultures will contain B lymphocytes as well as -myelomonocytic cells.
  • the stem cells may be administered in any physiologically acceptable medium, normally intravascularly, although they may also be introduced into bone or other convenient site, where the cells may find an appropriate site for regeneration and differentiation.
  • at least 1x10 s cells will be administered, preferably lxlO 6 or more.
  • the cells may be introduced by injection, catheter, or the like.
  • factors may also be included, such as the interleukins, e . g. IL-2, IL-3, IL-6, and IL-11, as well as the other interleukins, the colony stimulating factors, such as G-, M- and GM-CSF, interferons, e . g. 7-interferon, erythropoietin, etc.
  • the amount of these various factors will depend upon the purpose of the administration of the cells, the particular needs of the patient, and will normally be determined empirically.
  • the stem cell compositions which are employed will generally have fewer than 5% of lineage committed cells and will be capable of cell-free generation in a co- culture medium and differentiation to members of the lymphoid and myelomonocytic hematopoietic lineages. They will generally have at least 80% of the cells characterized by being human, hematopoietic, and being CD34 + 10- 19- 33- and Thy-1 + . In addition, they may when stained with rhodamine, be either rhodamine high or rhodamine low or a combination thereof. Preferably, the cells will be rhodamine low. See Spangrude, Immunol. Today (1989), 344-350.
  • the cells may be frozen at liquid nitrogen temperatures and stored for long periods of time, being thawed and capable of being reused.
  • the cells will usually be stored in a 10% DMSO, 50% FCS, 40% RPMI1640 medium. Once thawed, the cells may be expanded by use of growth factors and/or stromal cells associated with stem cell proliferation and differentiation.
  • the antibodies to CD34 were obtained from I.D. Bernstein (Andrews et al . , Blood (1986), 68, 1030) ; the antibody for Thy-1 was obtained from Fabre (Dalchau and Fabre, J. EX ⁇ . Med. (1979), 149, 576).
  • the antibodies for CD34 were detected using the appropriate anti-Ig conjugated to fluorescein, phycoerythin, or Texas red (Cal Tag) or bound to magnetic beads (Applied Immune Sciences [AIS]) and separated magnetically.
  • the Thy-1 antibody was a fluorescein, phycoerythrin or biotin conjugate, where the biotin conjugate was detected with Texas red-avidin (Cal Tag) .
  • Fluorescence Activated Cell Sorter Analysis and Sorting.
  • a Becton-Dickinson FACS modified as described (Parks and Herzenberg, Meth. Enzymol. (1984) , 108, 197) was employed.
  • the dual laser instrument allows for four fluorescent parameters and two light scatter parameters to be recorded for each analyzed cell. Residual erythrocytes and dead cells and debris were excluded from analysis by light scattering gating and propidium iodide (PI) staining or by scattering alone in four color analyses. Compensation for spatial overlaps of fluorescein and phycoerytherin and fluorescein and propidiu iodide was adjusted electronically.
  • the stained samples were maintained at 4°C throughout the sorting procedure. Sorted drops were collected in RPMI1640 containing 10% fetal calf serum. Following isolation of a cell population by FACS, the sample was diluted 1:1 in HBSS, centrifuged for 10 min at a rcf of 200 and resuspended in 50 or 100 ⁇ l of HBSS for hemocytometer counting.
  • the culture assays were performed as follows: AC6.21 confluent stromal cell layers were maintained for up to 3-4 weeks without passage by changing of the tissue culture medium every 5-7 days. To passage, the stomal cell layers were washed three times with serum-free medium, then overlaid with 2.5 ml (T-25 flask) of 0.5 mg/ l collagenase-dispase (Boehringer-Mannheim, Indianapolis, IN) in serum-free medium. The cultures were allowed to incubate 15-30 min at 37°C; then the cells in the enzyme-containing medium were collected in RPMI1640 medium with serum added.
  • stromal cells were suspended by pipetting with a Pasteur pipet, then cultured directly at one-fifth to one-fiftieth of the original cell concentration. Generally, confluent stromal layers ⁇ ubcultured at 1:10 reached confluency again at after 5-7 days. Subclones were obtained by limiting dilution culture from 30 to 0.3 cells per well. .
  • Cell suspensions of human fetal bone marrow were prepared from long bones of fetuses from 16-20 week gestation. The bones are split lengthwise and the medullary cavity is scraped with a scalpel blade. The bones are then placed in a 1 mg/ml solution of collagenase-dispase in RPMI1640.
  • bone marrow may be flushed from the marrow cavity without the collagenase-dispase treatment.
  • Cell suspensions are prepared from livers of 16-20 week gestation fetuses. The liver is minced and then pipetted to release cells. The cell suspension is then placed on Ficoll gradient to remove hepatocytes, red blood cells and debris. The hematopoietic cells are then harvested.
  • Ratio's marrow is obtained from aspirates, which are treated to remove red blood cells before use.
  • Bulk cultures are obtained by placing the human cells on the previously established confluent layer of mouse stromal cell lines. From 3xl0 4 to 2xl0 5 cells per ml are placed on the stromal cells in either T-25 flasks or six- well plates, by addition of 3 ml to each well of a six- well plate or 5 ml to a T-25 flask.
  • a 50:50 mixture of RPMI1640 and IMDM containing 50 U/ml penicillin/50 ⁇ g/ml streptomycin, 1 mM sodium pyruvate, 2 mM glutamine, 5xl0" 5 M 2-mercaptoethanol and 10% fetal calf serum is employed.
  • IMDM containing 50 U/ml penicillin/50 ⁇ g/ml streptomycin, 1 mM sodium pyruvate, 2 mM glutamine, 10% fetal calf serum, 20% horse serum and 10" 6 M hydrocortisone sodium succinate is employed. Bone marrow cells grown in the Dexter-type medium give rise only to myeloid differentiation.
  • Cultures were established with whole-cell populations or cells fractionated by their expression of cell surface antigens (CD34, Thy-l) .
  • CD34 cell surface antigens
  • Thy-l cell surface antigens
  • CD7 is a T-cell marker and not unexpectedly, T-cells were not observed, since there is no exposure to a thymic environment.
  • CD15 indicates onocytes and granulocytes, CD19 indicates B-cells and CD33 indicates myeloid cells.
  • frequency is intended the number of wells in which cells carrying the markers were observed of 15 wells (Table II) .
  • the stem cell populations in the in vitro cultures have the right surface markers and the right cell size and granularity (Paint-a-Gate) .
  • secondary in vitro cultures were prepared. The cells from 50 wells of the 24 hour treatment with LIF, IL-3 and IL-6 after 5 weeks were sorted for the CD34 Thy-1 populations. The total cells were about 5xl0 6 . After sorting, about 5xl0 5 of CD34 Thy-1 cells were obtained. These were promptly introduced into wells comprising confluent cultures of AC6.21 with long- term culture medium at about 100 cells per well. The following table indicates the results.
  • the amphotropic retroviral vector ⁇ Mo+PyF101- ⁇ R was employed. Valerio et al . , Gene (1989), 84, 419-427; and Bambesechem et al . , J. EXP. Med. (1990), 172, 729-736.
  • the infection was performed by introducing approximately 10 4 CD34 Thy-1 + cells and lxlO 6 CFU of the virus in 1 ml of long-term culture medium ("LTCM") comprising 10 ng/ml each of LIF, IL-3, IL-6, and GM-CSF.
  • LTCM long-term culture medium
  • the cell mixture was maintained for 24 hours, and the medium diluted to 10 ml with LTCM and 100 ⁇ l of the medium introduced into wells in which confluent layers of the AC6.21 stromal line was present.
  • the cells from 5-15 wells, each of the cells with and without virus, were then introduced into a methylcellulose culture and maintained for 2 weeks. At the end of this time, all cells were collected from each methylcellulose culture and analyzed by DNA PCR for the neo gene.
  • the anticipated fragment with primers for the neo gene was 180 bp.
  • Samples from cells which had not been selected with G418, and which were not exposed to the virus showed no band, while 3 samples from cells which had been exposed to the virus were positive.
  • the negative and positive controls for PCR were as expected.
  • a 2% agarose gel was employed for electrqphoretic separation.
  • the PCR products were digested with restriction enzyme SphI which provides 120 bp and 60 bp fragments, or * NcoI which provides 150 and 30 bp fragments.
  • SphI restriction enzyme which provides 120 bp and 60 bp fragments
  • * NcoI which provides 150 and 30 bp fragments.
  • the uninfected cells and infected cells were studied to determine their ability to provide long-term T-cell reconstitution in the thymus of the SCID- hu/thymus model, where fetal thymus is introduced into the kidney capsule of a C.B.17 scid/scid mouse.
  • the cells which are employed for culture differ in HLA from the cells of the thymus. (See PCT/US91/02373 for a description of the test procedure.) 10 4 CD34 Thy-1 cells from five-week cultures, where the cells had originally been exposed for 24 hours to LIF plus IL-3 plus IL-6 or these factors plus virus as described previously and allowed to grow for five weeks, were employed.
  • the cells were sorted for CD34 Thy-1 for injection into the thymus.
  • FACS analysis showed the presence of T-cells observed by markers for the surface membrane proteins CD3, CD4 and CD8 in conjunction with a marker for the HLA of the donor cells in two or three studies.
  • T-cell markers were employed as against an antibody for all human cells, in the same two or three experiments, a large population of T-cells were observed.
  • the cells in the thymus were isolated and subjected to DNA PCR analysis. Where the primers employed were for the neo gene, employing a total of 10 6 cells from the thymus, a control mouse gave a negative result, while a positive result is observed under the following conditions: 3 months after injection CD34 + Thy-1 + positive cells from a secondary culture at 10 4 cells/thymus; 2.5 months after injection of CD34 + Thy-1 + positive cells from a primary culture, 2x10 3 cells/thymus; 5 months after injection of CD34 + Thy-1 + cells from a primary culture, at 10 4 cells ⁇ thymus. Analogous results were observed for the polyoma enhancer.
  • pluripotent hematopoietic stem cells can be grown for extended periods of time, substantially expanded, in culture, while retaining pluripotency.
  • stem cells may be obtained from a wide variety of sources, fetal or adult, bone marrow or blood, and grown, so as to have an expanded source of the cells.
  • cells may be infected with appropriate retroviruses, where the cells will integrate the retroviral construct with functional expression of a gene contained within the construct, where in cells after differentiation and maturation, the gene is retained and will be expressed.

Abstract

Des cellules souches hématopoïétiques humaines peuvent être cultivées dans une culture de longue durée, en particulier des cultures combinées avec une lignée cellulaire appropriée du stroma, et plus particulièrement en présence d'un facteur inhibiteur de leucémie, seul ou en combinaison avec d'autres facteurs. L'on a découvert que les cellules conservent leur fonction, comme démontré par un dosage in vivo de lymphocytes T, ainsi que leur aptitude à former des colonies d'autres lignées dans la méthylcellulose. La transfection des cellules peut être effectuée au moyen d'un virus, des résultats améliorés étant obtenus en présence du facteur inhibiteur de leucémie et, éventuellement, d'autres facteurs hématopoïétiques.
PCT/US1993/001852 1992-03-04 1993-03-03 Culture de cellules souches hematopoietiques et leur preparation par genie genetique WO1993018137A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP5515827A JPH07504331A (ja) 1992-03-04 1993-03-03 造血幹細胞の培養およびその遺伝子工学
AU37839/93A AU680406B2 (en) 1992-03-04 1993-03-03 Culturing of hematopoietic stem cells and their genetic engineering
KR1019940703107A KR950700403A (ko) 1992-03-04 1993-03-03 조혈 간세포의 배양 및 그것의 유전공학(culturing of hematopoietic stem cells and their genetic engineering)
EP93907130A EP0631618A4 (fr) 1992-03-04 1993-03-03 Culture de cellules souches hematopoietiques et leur preparation par genie genetique.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84678292A 1992-03-04 1992-03-04
US07/846,782 1992-03-04

Publications (1)

Publication Number Publication Date
WO1993018137A1 true WO1993018137A1 (fr) 1993-09-16

Family

ID=25298935

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/001852 WO1993018137A1 (fr) 1992-03-04 1993-03-03 Culture de cellules souches hematopoietiques et leur preparation par genie genetique

Country Status (6)

Country Link
EP (1) EP0631618A4 (fr)
JP (1) JPH07504331A (fr)
KR (1) KR950700403A (fr)
AU (2) AU680406B2 (fr)
CA (1) CA2131368A1 (fr)
WO (1) WO1993018137A1 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
WO1996009400A1 (fr) * 1994-09-19 1996-03-28 Systemix, Inc. Procedes permettant de modifier genetiquement des cellules souches hematopoietiques
WO1996021004A1 (fr) * 1994-12-30 1996-07-11 Boehringer Ingelheim International Gmbh Techniques de production de cellules differenciees a partir de cellules hematopoietiques immatures
WO1996033281A1 (fr) * 1995-04-20 1996-10-24 Chiron Corporation Transduction ex vivo a productivite elevee de cellules souches hematopoietiques au moyen de preparations retrovirales xenotropes recombinees
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1997018298A1 (fr) * 1995-11-14 1997-05-22 Regents Of The University Of Minnesota Culture ex vivo de cellules souches
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
WO1997029183A2 (fr) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes et compositions pour transformer des cellules dendritiques et activer des lymphocytes t
WO1997032992A1 (fr) * 1996-03-07 1997-09-12 Amba Biosciences, L.L.C. Lignees cellulaires hematopoietiques immortalisees, systeme cellulaire de ces lignees avec des cellules du stroma, applications in vitro, ex vivo et in vivo, et generation in vivo de cellules dendritiques et de macrophages
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
EP0873049A1 (fr) * 1995-09-29 1998-10-28 Indiana University Foundation Procedes pour ameliorer le transfert d'adn par mediation virale, en utilisant des molecules avec des domaines permettant une fixation sur le virus et sur la cellule
WO1999022001A1 (fr) * 1997-10-28 1999-05-06 Kirin Beer Kabushiki Kaisha Procede de regulation de la differenciation/ proliferation des cellules souches hematopoietiques
WO1999053022A2 (fr) * 1995-12-29 1999-10-21 University Of Edinburgh Cellules specifiques de lignee et cellules souches
WO1999061644A1 (fr) * 1998-05-29 1999-12-02 Case Western Reserve University Transduction genique des cellules progenitrices hematopoietiques
WO2000050568A2 (fr) * 1999-02-24 2000-08-31 Reneuron Limited Transplantation de cellules hematopoietiques
WO2000070022A2 (fr) * 1999-05-14 2000-11-23 City Of Hope Expansion ex vivo de cellules souches hematopoietiques multipotentes mammaliennes
WO2001032841A2 (fr) * 1999-10-29 2001-05-10 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Methode de differentiation in vitro de lymphocytes t generes a partir de cellules souches cd34?+¿
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US6835566B2 (en) 1998-02-23 2004-12-28 Aastrom Biosciences, Inc. Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
US7048921B2 (en) 1995-09-12 2006-05-23 Reneuron Limited Neural transplantation using pluripotent neuroepithelial cells
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
US7416888B2 (en) 2004-09-30 2008-08-26 Reneuron Limited Cell lines
WO2014135924A1 (fr) 2013-03-08 2014-09-12 Cells For Cells Cellules souches de sang menstruel pour le soutien et le développement efficaces des cellules souches hématopoïétiques cd34+ et cd133+ in vitro

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086330A1 (fr) * 1990-07-09 1992-01-10 Richard C. Fry Amelioration de l'implantation, du developpement et du maintien des embryons au moyen d'un facteur inhibiteur de la leucemie

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Blood, Volume 76, No. 6, issued 15 September 1990, F.A. FLETCHER et al., "Murine Leukemia Inhibitory Factor Enhances Retroviral-Vector Infection Efficiency of Hematopoietic Progenitors", pages 1098-1103, see especially page 1099. *
Blood, Volume 77, No. 2, issued 15 January 1991, C. VERFAILLIE et al., "Leukemia Inhibitory Factor/Human Interleukin for DA Cells: A Growth Factor that Stimulates the In Vitro Development of Multipotential Human Hematopoietic Progenitors", pages 263-270, see entire document. *
Gene, Volume 84, issued 1989, D. VALERIO, "Retrovirus-Mediated Gene Transfer into Embryonal Carcinoma and Hematopoietic Stem Cells: Expression from a Hybrid Long Terminal Repeat", pages 419-427, see entire document. *
Journal of Experimental Medicine, Volume 172, issued September 1990, V.W. VAN BEUSECHEM et al., "Expression of Human Adenosine Deaminase in Mice Transplanted with Hematopoietic Stem Cells Infected with Amphotropic Retroviruses", pages 729-736, see entire document. *
Nature, Volume 336, issued 15 December 1988, J.-F. MOREAU et al., "Leukaemia Inhibitory Factor is Identical to the Myeloid Growth Factor Human Interleukin for DA Cells", pages 690-692, see entire document. *
R.I. FRESHNEY, "Culture of Animal Cells: A Manual of Basic Techniques", published 1987 by Alan R. Liss, Inc. (N.Y.), see pages 60-61, 139-140. *
See also references of EP0631618A4 *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667034B2 (en) 1989-06-15 2003-12-23 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture, methods for assaying the effect of substances on lineage-specific cell production, and cell compositions produced by these cultures
US5437994A (en) * 1989-06-15 1995-08-01 Regents Of The University Of Michigan Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US7083979B1 (en) 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
US7759467B2 (en) 1994-03-25 2010-07-20 Indiana University Research And Technology Corporation Enhanced mediated DNA transfer
WO1996009400A1 (fr) * 1994-09-19 1996-03-28 Systemix, Inc. Procedes permettant de modifier genetiquement des cellules souches hematopoietiques
US5648248A (en) * 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
WO1996021004A1 (fr) * 1994-12-30 1996-07-11 Boehringer Ingelheim International Gmbh Techniques de production de cellules differenciees a partir de cellules hematopoietiques immatures
WO1996033281A1 (fr) * 1995-04-20 1996-10-24 Chiron Corporation Transduction ex vivo a productivite elevee de cellules souches hematopoietiques au moyen de preparations retrovirales xenotropes recombinees
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
US7048921B2 (en) 1995-09-12 2006-05-23 Reneuron Limited Neural transplantation using pluripotent neuroepithelial cells
US7371374B2 (en) 1995-09-12 2008-05-13 Reneuron Limited Neural transplantation using pluripotent neuroepithelial cells
US8889419B2 (en) 1995-09-29 2014-11-18 Indiana University Research & Technology Corporation Methods for enhanced virus-mediated DNA transfer using molecules with virus- and cell-binding domains
EP0873049A1 (fr) * 1995-09-29 1998-10-28 Indiana University Foundation Procedes pour ameliorer le transfert d'adn par mediation virale, en utilisant des molecules avec des domaines permettant une fixation sur le virus et sur la cellule
EP0873049A4 (fr) * 1995-09-29 1998-12-02
US5922597A (en) * 1995-11-14 1999-07-13 Regents Of The University Of Minnesota Ex vivo culture of stem cells
WO1997018298A1 (fr) * 1995-11-14 1997-05-22 Regents Of The University Of Minnesota Culture ex vivo de cellules souches
WO1999053022A2 (fr) * 1995-12-29 1999-10-21 University Of Edinburgh Cellules specifiques de lignee et cellules souches
WO1999053022A3 (fr) * 1995-12-29 2001-04-19 Univ Edinburgh Cellules specifiques de lignee et cellules souches
US7378277B2 (en) 1996-02-08 2008-05-27 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
WO1997029183A3 (fr) * 1996-02-08 1997-12-18 Us Health Procedes et compositions pour transformer des cellules dendritiques et activer des lymphocytes t
WO1997029183A2 (fr) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes et compositions pour transformer des cellules dendritiques et activer des lymphocytes t
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
WO1997032992A1 (fr) * 1996-03-07 1997-09-12 Amba Biosciences, L.L.C. Lignees cellulaires hematopoietiques immortalisees, systeme cellulaire de ces lignees avec des cellules du stroma, applications in vitro, ex vivo et in vivo, et generation in vivo de cellules dendritiques et de macrophages
US5811297A (en) * 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
WO1999022001A1 (fr) * 1997-10-28 1999-05-06 Kirin Beer Kabushiki Kaisha Procede de regulation de la differenciation/ proliferation des cellules souches hematopoietiques
US6835566B2 (en) 1998-02-23 2004-12-28 Aastrom Biosciences, Inc. Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
US6929948B1 (en) 1998-04-14 2005-08-16 The University Court Of The University Of Edinburgh Lineage specific cells and progenitor cells
US7781214B2 (en) 1998-04-14 2010-08-24 The University Court Of The University Of Edinburgh Lineage specific cells and progenitor cells
WO1999061644A1 (fr) * 1998-05-29 1999-12-02 Case Western Reserve University Transduction genique des cellules progenitrices hematopoietiques
WO2000050568A3 (fr) * 1999-02-24 2000-12-07 Reneuron Ltd Transplantation de cellules hematopoietiques
WO2000050568A2 (fr) * 1999-02-24 2000-08-31 Reneuron Limited Transplantation de cellules hematopoietiques
WO2000070022A2 (fr) * 1999-05-14 2000-11-23 City Of Hope Expansion ex vivo de cellules souches hematopoietiques multipotentes mammaliennes
WO2000070022A3 (fr) * 1999-05-14 2001-05-31 Hope City Expansion ex vivo de cellules souches hematopoietiques multipotentes mammaliennes
WO2001032841A3 (fr) * 1999-10-29 2002-02-07 Us Health Methode de differentiation in vitro de lymphocytes t generes a partir de cellules souches cd34?+¿
WO2001032841A2 (fr) * 1999-10-29 2001-05-10 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Methode de differentiation in vitro de lymphocytes t generes a partir de cellules souches cd34?+¿
US7416888B2 (en) 2004-09-30 2008-08-26 Reneuron Limited Cell lines
US7419827B2 (en) 2004-09-30 2008-09-02 Reneuron Limited Cell lines
US7666672B2 (en) 2004-09-30 2010-02-23 Reneuron Limited Cell lines
WO2014135924A1 (fr) 2013-03-08 2014-09-12 Cells For Cells Cellules souches de sang menstruel pour le soutien et le développement efficaces des cellules souches hématopoïétiques cd34+ et cd133+ in vitro

Also Published As

Publication number Publication date
AU3783993A (en) 1993-10-05
KR950700403A (ko) 1995-01-16
JPH07504331A (ja) 1995-05-18
CA2131368A1 (fr) 1993-09-16
AU680406B2 (en) 1997-07-31
AU4369097A (en) 1998-02-12
EP0631618A4 (fr) 1995-09-27
EP0631618A1 (fr) 1995-01-04

Similar Documents

Publication Publication Date Title
AU680406B2 (en) Culturing of hematopoietic stem cells and their genetic engineering
CA2195335C (fr) Lignees cellulaires stromales de la moelle humaine entretenant l'hematopoiese
US5061620A (en) Human hematopoietic stem cell
EP0330191B1 (fr) ADN encodant CD40
Whitlock et al. Murine B cell lymphopoiesis in long term culture
Larochelle et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy
US6541249B2 (en) Immortalized human stromal cell lines
US5677139A (en) In vitro differentiation of CD34+ progenitor cells into T lymphocytes
US7416887B2 (en) Methods for use of MPL ligands with primitive human stem cells
US5821108A (en) Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
Yamaguchi et al. Umbilical vein endothelial cells are an important source of c‐kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells
Rios et al. Systematic analysis of the ability of stromal cell lines derived from different murine adult tissues to support maintenance of hematopoietic stem cells in vitro
Kisielow Applications of fetal thymus organ cultures in studies of T cell development
WO2002064756A9 (fr) Auto-renouvellement de cellules souches et engagement de lignees
WO1994008039A1 (fr) Procede d'enrichissement de cellules souches hematopoietiques humaines a l'aide de la proteine c-kit
WO2003065986A2 (fr) Lignees de mastocytes humains contenant le recepteur fceri
WO1997022708A1 (fr) Cellules souches hematopoietiques embryonnaires de primate, formant des groupements
WO1994010293A1 (fr) Cultures des cellules stromales thymiques permettant la differenciation des lymphoocytes t

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR SK

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: KZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2131368

Country of ref document: CA

Ref document number: 1993907130

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993907130

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993907130

Country of ref document: EP